Childhood obesity affects approximately 390 million children and adolescents globally and is a major predictor of adult cardiometabolic disease, type 2 diabetes, and psychological comorbidity. Family-based lifestyle interventions are first-line; pharmacotherapy with semaglutide has now received regulatory approval in adolescents with obesity. Early prevention through school, community, and policy-level interventions is recognised as the most impactful long-term approach.
Loading articles...
